Avalo CMO exercises options, sells 3,970 shares
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold the resulting shares in a planned transaction.
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, Doyle exercised options to acquire 3,970 shares of common stock at $12.65 per share, then sold all 3,970 shares in open-market trades at an average price of about $18.01, with individual trades ranging from $18.00 to $18.10. Following the sale, Doyle directly held 3,622 shares of common stock and 210,530 stock options. The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, and that the underlying option vests over four years, with 25% vesting on July 15, 2025 and the remainder in equal monthly installments over the next three years.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,970 shares ($21K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
3,970 shs ($72K)
Approx. gross sale proceeds
$72K
Approx. exercise cost
$50K
Approx. pre-tax spread
$21K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,970 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,970 | $12.65 | $50K |
| Sale | Common Stock | 3,970 | $18.0122 | $72K |
Holdings After Transaction:
Stock Option (Right to Buy) — 210,530 contracts (Direct);
Common Stock — 3,622 shares (Direct)
Footnotes (3)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options exercised: 3,970 shares
Option exercise price: $12.65 per share
Shares sold: 3,970 shares
+5 more
8 metrics
Options exercised
3,970 shares
Stock option exercise on April 6, 2026
Option exercise price
$12.65 per share
Strike price for exercised stock option
Shares sold
3,970 shares
Open-market sale on April 6, 2026
Average sale price
$18.0122 per share
Common stock sale price
Sale price range
$18.00–$18.10 per share
Multiple transactions within this range
Shares held after sale
3,622 shares
Direct common stock holdings post-transaction
Options held after exercise
210,530 options
Total stock options following the transaction
Option expiration
July 15, 2034
Expiration date of the stock option
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), open-market sale, vesting, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AVTX Chief Medical Officer Mittie Doyle report?
Mittie Doyle reported exercising stock options for 3,970 Avalo Therapeutics shares at $12.65 and selling all 3,970 shares in open-market trades around $18.01. The moves were part of routine equity compensation management rather than an open-market share purchase.
Was Mittie Doyle’s AVTX stock sale under a Rule 10b5-1 trading plan?
Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Such pre-arranged plans schedule trades in advance, reducing the significance of day-to-day market timing decisions for these sales.
What are the key terms of the stock option exercised by Mittie Doyle at Avalo Therapeutics?
The exercised stock option carried a $12.65 strike price and an expiration date of July 15, 2034. It vests 25% on July 15, 2025, with remaining shares vesting in equal monthly installments over three years, contingent on continued service with Avalo Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
